...that paragraph to me is more about the beneficial effect + outcome in early MPC treatment on limiting deleterious scar tissue replacement and subsequent reduction in LVEF rather than a description of specific MOA. I am intrigued by his reference to endothelium controlled signal pathways, disruption of which between endothelium and cardiocytes "has been implicated" in cardiac structural/functionsl abnormalities.
I guess I'm curious about MPC cardiac regenerative effects as well as immunomodulatory inflammatory effects that impede scar tissue + general degradation in myocardial function, control of which by itself may explain the beneficial results observed.
Nice. Thanks. More reading to do.
MSB's year is upon us. Strap in.
Ann: Half Year Financial Results Presentation, page-75
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.050(4.65%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.13 | $1.07 | $5.964M | 5.444M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25000 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 176236 | 7 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.12 |
Change
0.050 ( 4.69 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.13 | $1.07 | 829227 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| MSB (ASX) Chart |